BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

EXP upcoming catalysts

Eagle Pharmaceuticals, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 1 FDA event(s). Subscribe to EXP (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-13Complete response lettercomplete responseEagle Pharmaceuticals, Inc. EXPFulvestrantCRL 2026-04-13: Eagle Pharmaceuticals, Inc. NDA 220045 (Fulvestrant Injection)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-02-10 est.P2Eagle Pharmaceuticals, Inc. EXPNCT05776004 Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial PneumoniaPneumonia, Bacterialactive not recruiting276

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.